{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:30:06Z","timestamp":1787905806284,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd009650.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000}}],"reference-count":158,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009650.pub5","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T10:13:40Z","timestamp":1670926420000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis"],"prefix":"10.1002","volume":"2023","author":[{"given":"David KH","family":"Lo","sequence":"additional","affiliation":[{"name":"Ward 12; Leicester Royal Infirmary; Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne S","family":"Muhlebach","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pulmonary Medicine; University of North Carolina; Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics & Gynaecology; School of Medicine, University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"10.1002\/14651858.CD009650.pub5-BIB0001|cit1","first-page":"123","article-title":"Design of a clinical trial to eradicate persistent MRSA: the path from hypothesis to implementation","volume":"47 Suppl","author":"Dasenbrook","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0002|cit2","first-page":"314","article-title":"Update on the persistent methicillin-resistant Staphylococcus aureus eradication protocol (PMEP) trial","volume":"50 Suppl 41","author":"Dezube","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2018.07.005","article-title":"Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis","volume":"18","author":"Dezube","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD009650.pub5-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1745-6215-15-223","article-title":"Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis - the PMEP trial: study protocol for a randomized controlled trial","volume":"15","author":"Jennings","year":"2014","journal-title":"Trials"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD009650.pub5-BIB0005|cit5","first-page":"361","article-title":"Results of the persistent methicillin-resistant Staphylococcus aureus eradication protocol (PMEP) trial","volume":"52","author":"Jennings","year":"2017","journal-title":"Pediatric\u00a0Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0006|cit6","unstructured":"Persistent methicillin resistant Staphylococcus aureus eradication protocol (PMEP) clinicaltrials.gov\/ct2\/show\/NCT01594827"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"e0213497","DOI":"10.1371\/journal.pone.0213497","article-title":"Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: a randomized multicenter study","volume":"14","author":"Dolce","year":"2019","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0008|cit8","unstructured":"MRSA study www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-000219-25-IT"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0009|cit9","first-page":"309","article-title":"Early antibiotic treatment for MRSA eradication in cystic fibrosis patients: a multicenter RCT","volume":"51 Suppl 45","author":"Neri","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1569-1993(15)30007-2","article-title":"Efficacy of a protocol for eradication of newly acquired MRSA: results of the STAR-too trial","volume":"14 Suppl 1","author":"Goss","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/thoraxjnl-2016-208949","article-title":"Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial","volume":"72","author":"Muhlebach","year":"2017","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/thoraxjnl-2016-208949","article-title":"Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial","volume":"72","author":"Muhlebach","year":"2017","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0013|cit13","first-page":"275","article-title":"Occurrence of high-persister strains of MRSA in cystic fibrosis","volume":"54 Suppl 2","author":"Muhlebach","year":"2019","journal-title":"Pediatric\u00a0Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0014|cit14","first-page":"327","article-title":"MRSA types in new onset infection-results from Star-Too trial","volume":"50 Suppl 41","author":"Muhlebach","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0015|cit15","unstructured":"Early methicillin-resistant Staphylococcus aureus (MRSA) therapy in cystic fibrosis (CF) (STAR-Too) clinicaltrials.gov\/ct2\/show\/NCT01349192"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0016|cit16","first-page":"350","article-title":"Risk factors for methicillin-resistant staphylococcus aureus (MRSA) persistence in persons with cystic fibrosis (CF): analysis of the star-too cohort","volume":"52 Suppl 47","author":"Somayaji","year":"2017","journal-title":"Pediatric\u00a0Pulmonology"},{"issue":"S22","key":"10.1002\/14651858.CD009650.pub5-BIB0017|cit17","first-page":"288","article-title":"A double blind randomised study to compare the safety and tolerance of differing concentrations of nebulised colistin administered using HaloLite in cystic fibrosis (CF) patients","volume":"32","author":"Adeboyeku","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0018|cit18","first-page":"123s","article-title":"Home intravenous therapy in adult cystic fibrosis patients. The impact on lung function and quality of life","volume":"16 Suppl 31","author":"Amelina","year":"2000","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0019|cit19","first-page":"S40","article-title":"Incidence and treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients: a cohort study","volume":"51 Suppl 42","author":"Bittencourt","year":"2016","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/0007-0971(87)90184-7","article-title":"A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with\u00a0cystic fibrosis","volume":"81","author":"Carswell","year":"1987","journal-title":"British Journal of Diseases of the Chest"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0021|cit21","first-page":"537","article-title":"Bronchial response of children with cystic fibrosis to nebulised antibiotics","volume":"20","author":"Chua","year":"1990","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009650.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1183\/09031936.93.03101114","article-title":"Bronchial response to nebulized antibiotics in children with cystic fibrosis","volume":"3","author":"Chua","year":"1990","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ppul.21376","article-title":"Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis","volume":"46","author":"Coates","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S1569-1993(09)60261-7","article-title":"Lung delivery of a new tobramycin nebuliser solution (150mg\/1.5ml) by an investigational eFlow\u00ae nebuliser is equivalent to TOBI\u00ae but in a fraction of time","volume":"8 Suppl 2","author":"Denk","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60085-9","article-title":"In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150mg\/1.5ml) administered by the eFlow\u00ae electronic nebuliser compared to TOBI\u00ae in the PARI LC PLUS\u00ae","volume":"9 Suppl 1","author":"Keller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0026|cit26","first-page":"S256","article-title":"Ceftazidime 3G BD is as effective as ceftazidime 2G TDS in the treatment of respiratory exacerbations in cystic fibrosis","volume":"32 Suppl","author":"Conway","year":"1996","journal-title":"Israel Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0027|cit27","first-page":"A242","article-title":"Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis","volume":"131","author":"Cooper","year":"1985","journal-title":"American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0028|cit28","unstructured":"Prospective trial to evaluate the effect of nebulized vancomycin in children with cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2020\/06\/025699"},{"issue":"1","key":"10.1002\/14651858.CD009650.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcf.2012.06.005","article-title":"A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF","volume":"12","author":"Dalb\u00f8ge","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0030|cit30","first-page":"149","article-title":"Emerging therapies in cystic fibrosis: aerovanc for the treatment of chronic MRSA","volume":"50 Suppl 41","author":"Dasenbrook","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0031|cit31","first-page":"298","article-title":"Pharmacokinetics of vancomycin in plasma and sputum following pulmonary administration in cystic fibrosis patients with persistent methicillin-resistant Staphylococcus aureus infection","volume":"51 Suppl 45","author":"Marich","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0032|cit32","unstructured":"Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients clinicaltrials.gov\/ct2\/show\/NCT01746095"},{"issue":"6","key":"10.1002\/14651858.CD009650.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1128\/AAC.31.6.915","article-title":"Pharmacokinetics of ciprofloxacin in cystic fibrosis","volume":"31","author":"Davis","year":"1987","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009650.pub5-BIB0034|cit34","first-page":"99","article-title":"The effect of frequent exposure to gentamicin on distortion product OAEs in patients with cystic fibrosis","volume":"30","author":"Degg","year":"1996","journal-title":"British Journal of Audiology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0035|cit35","first-page":"322","article-title":"Tobramycin and hyaluronic acid nasal solution: beyond antimicrobial effect","volume":"46 Suppl 34","author":"Claut","year":"2011","journal-title":"Pediatric\u00a0Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jcf.2014.02.006","article-title":"Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis","volume":"13","author":"Di Cicco","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0037|cit37","unstructured":"Pilot study to evaluate the local tolerability and efficacy of a new tobramycin 3% nasal spray formulation to reduce the bacterial density of Pseudomonas aeruginosa and\/or Staphylococcus aureus, in patients affected by Cystic Fibrosis with rhinosinusal infection - ND www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-003628-39-IT"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0038|cit38","unstructured":"Dodd M Maddison J Abbott J Webb AK The effect of the tonicity of nebulised colistin on lung function in adults with cystic fibrosis 18th European Cystic Fibrosis Conference; 1993 May 21-26; Madrid, Spain 1993 121"},{"issue":"7","key":"10.1002\/14651858.CD009650.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/thx.52.7.656","article-title":"Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis","volume":"52","author":"Dodd","year":"1997","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0040|cit40","first-page":"515s","article-title":"The effect of the tonicity of nebulised colistin on chest tightness and lung function in adults with cystic fibrosis","volume":"6 Suppl 17","author":"Dodd","year":"1993","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0041|cit41","first-page":"389","article-title":"Is medicine evidence-based when there is discrepancy between patient reported and objective measures of compliance in clinical trials?","volume":"26 Suppl 17","author":"Dodd","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0042|cit42","unstructured":"Does nebulised tobramycin (TOBI) via e-flow delivery systems cause a raised peak serum tobramycin level in children with Cystic Fibrosis? - TOBICF www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-005346-20-GB"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0043|cit43","unstructured":"A Phase I\/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cystic Fibrosis (CF) - VR496\/005- Orally inhaled heparin in patients with Cystic Fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-006276-11-GB"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0044|cit44","unstructured":"Etude pharmacocinetique de l\u2019equivalence de la biodisponibilite entre Nebcinal\u00ae 150mg\/3ml administre par Aeroneb\u00ae Idehaler\u00ae et Tobi\u00ae 300mg\/5ml administre par Pari LC Plus \u00ae www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-013660-39-FR"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0045|cit45","unstructured":"Etude pharmacocinetique de l\u2019equivalence de la biodisponibilite entre Nebcinal\u00ae 150mg\/3ml administre par Aeroneb\u00ae Idehaler\u00ae et Tobi\u00ae 300mg\/5ml administre par Pari LC Plus \u00ae \/Pulmoaid \u00ae chez des patients atteints de mucoviscidose www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-023533-34-FR"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0046|cit46","unstructured":"Randomized clinical trial to assess the effect of nebulized bicarbonate on bacterial infections in patients with cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-004033-25-ES"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0047|cit47","unstructured":"A study of safety, tolerability and effect of SNSP113 in cystic fibrosis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2019-003178-25-HU"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD009650.pub5-BIB0048|cit48","first-page":"A2239","article-title":"Phase 2b study of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection","volume":"181","author":"Conrad","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60087-2","article-title":"Effects of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection","volume":"9 Suppl 1","author":"Flume","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Flume P VanDevanter DR Cohen F Fleming R Elborn JS Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials Journal of Cystic Fibrosis 2015 14 Suppl 1 S87","DOI":"10.1016\/S1569-1993(15)30294-0"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(11)60105-7","article-title":"Effects of inhaled MP-376 (Aeroquin\u2122 levofloxacin inhalation solution) on cystic fibrosis patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) lung infection","volume":"10 Suppl 1","author":"Flume","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD009650.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009650.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0054|cit54","first-page":"301","article-title":"Effects of inhaled MP-376 (aeroquin, levofloxacin inhalation solution) on the need for other anti-pseudomonal antimicrobials in stable CF patients with chronic pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Geller","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0058|cit58","unstructured":"MP-376 (Aeroquin\u2122, Levofloxacin for Inhalation) in patients with cystic fibrosis clinicaltrials.gov\/show\/nct01180634"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0059|cit59","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Van Devanter","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0060|cit60","first-page":"246","article-title":"Effect of aerosolised rhDnase (Pulmozyme\u00ae) on pulmonary infections in CF: an open randomised study","volume":"Suppl 20","author":"Frederiksen","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD009650.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/08035250600752466","article-title":"Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis","volume":"95","author":"Frederiksen","year":"2006","journal-title":"Acta Paediatrica"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jhin.2003.12.003","article-title":"Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection","volume":"56","author":"Garske","year":"2004","journal-title":"Journal of Hospital Infection"},{"issue":"7","key":"10.1002\/14651858.CD009650.pub5-BIB0063|cit63","first-page":"A391","article-title":"The effects of doubling concentration of tobramycin solution for inhalation on pharmacokinetics (PK), safety and delivery time in patients with cystic fibrosis (CF)","volume":"169","author":"Geller","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009650.pub5-BIB0064|cit64","first-page":"A386","article-title":"Serum pharmacokinetics of two preparations of tobramycin solution for inhalation in young cystic fibrosis patients","volume":"169","author":"Rosenfeld","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/j.1552-4604.1986.tb02938.x","article-title":"Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis","volume":"26","author":"Goldfarb","year":"1986","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0066|cit66","first-page":"315","article-title":"A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients","volume":"43 Suppl 31","author":"Geller","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60101-0","article-title":"Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications","volume":"7 Suppl 2","author":"Griffith","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(11)60106-9","article-title":"Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis","volume":"10 Suppl 1","author":"Kearns","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD009650.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17476348.2015.986469","article-title":"Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis","volume":"9","author":"Stockmann","year":"2015","journal-title":"Expert Review of Respiratory Medicine"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0070|cit70","unstructured":"Gulliver T Wilson S Williams G Harris M Cooper D Nebulized tobramycin (intravenous solution) is tolerated without inducing cough and wheeze in cystic fibrosis patients Thoracic Society of Australia & New Zealand Annual Scientific Meeting; 2003 April 4-9; Adelaide, Australia 2003 A139"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.rmed.2015.01.013","article-title":"Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre","volume":"109","author":"Hall","year":"2015","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009650.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2007-1025191","article-title":"Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration","volume":"205","author":"Heininger","year":"1993","journal-title":"Klinische Padiatrie"},{"issue":"18","key":"10.1002\/14651858.CD009650.pub5-BIB0073|cit73","first-page":"1614","article-title":"Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life","volume":"85","author":"Hjelte","year":"1988","journal-title":"Lakartidningen"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0074|cit74","first-page":"305","article-title":"An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled alginate oligosaccharide delivered as a dry powder and as a nebulised solution in cystic fibrosis patients","volume":"49 Suppl 38","author":"Hodges","year":"2014","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0075|cit75","first-page":"354","article-title":"Evaluation of antibiotic therapy in patients with cystic fibrosis","volume":"76","author":"Huang","year":"1979","journal-title":"Chest"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0076|cit76","unstructured":"Huang NN Palmer J Braverman S Keith HH Schidlow D Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study 23rd Annual Meeting Cystic Fibrosis Club Abstracts; 1982 May 14; Washington D.C 1982 124"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0077|cit77","first-page":"279","article-title":"Impaired lung function influences the serum concentration of inhaled drugs in cystic fibrosis","volume":"30 Suppl 20","author":"App","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0078|cit78","unstructured":"Huls G App EM Bittner-Dersch P Stolz S Lindemann H Impaired lung function influences the serum concentration of inhaled drugs in cystic fibrosis 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden 2000 177"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0079|cit79","first-page":"291","article-title":"Once daily dosage of intravenous tobramycin - increased risk for cochlea damage in children with cystic fibrosis","volume":"32 Suppl 22","author":"Junge","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0080|cit80","unstructured":"Kruger K Junge S Schonweiler R Ptok M Ballmann M Once daily dosage of intravenous tobramycin in patients with cystic fibrosis - increased risk for cochlea damage? 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P191"},{"issue":"10","key":"10.1002\/14651858.CD009650.pub5-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/ppul.23519","article-title":"Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: a single center observational study","volume":"51","author":"Kappler","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0082|cit82","unstructured":"Kapranov NI Belousov YB Kashyrskaya NY Smirnova EY Quinoline therapy in children with cystic fibrosis 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium 1995 P19"},{"issue":"7","key":"10.1002\/14651858.CD009650.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.01797-10","article-title":"Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0084|cit84","unstructured":"Khorasani EN Mansouri F Effect of zinc supplementation on respiratory infections in children with cystic fibrosis European Respiratory Society Annual Congress; 2009; Sept 12-16; Vienna, Austria 2009 722s"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0085|cit85","unstructured":"Knight RK Batten JC Mearns M A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, the Netherlands 1979 52"},{"issue":"7","key":"10.1002\/14651858.CD009650.pub5-BIB0086|cit86","first-page":"A307","article-title":"Does inhalation of preservatives from IV tobramycin preparations (TOB) cause airway inflammation?","volume":"169","author":"Labiris","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0022-3476(79)80785-4","article-title":"A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis","volume":"95","author":"Loening-Baucke","year":"1979","journal-title":"Journal of Pediatrics"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD009650.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1203\/00006450-197804001-00795","article-title":"Cephalexin in cystic fibrosis: a placebo-controlled study","volume":"12","author":"Loening-Baucke","year":"1978","journal-title":"Pediatric Research"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0089|cit89","unstructured":"Loening-Bauke VA Mischler EH Myers MG Cephalexin compared to placebo in the management of patients with cystic fibrosis 19th Annual Meeting Cystic Fibrosis Club Abstracts; 1978 April 25; New York, NY 1978 69"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhin.2006.10.011","article-title":"Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol","volume":"65","author":"Macfarlane","year":"2007","journal-title":"Journal of Hospital Infection"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/(SICI)1099-0496(199810)26:4<287::AID-PPUL9>3.0.CO;2-#","article-title":"Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis","volume":"26","author":"Maiz","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0092|cit92","unstructured":"Nathanson I Cropp GJ Li P Neter E Effectiveness of aerosolized gentamicin in cystic fibrosis (CF) Cystic Fibrosis Club Abstracts; 1985 1985 145"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0093|cit93","unstructured":"Epidemiology and treatment of small-colony variant staphylococcus aureus in cystic fibrosis clinicaltrials.gov\/show\/nct02547116"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0094|cit94","unstructured":"A study of AeroVanc for the treatment of MRSA infection in CF patients Staphylococcus aureus clinicaltrials.gov\/ct2\/show\/NCT03181932"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0095|cit95","unstructured":"A study of the safety and tolerability of inhaled SNSP113 in healthy subjects and subjects with stable cystic fibrosis clinicaltrials.gov\/show\/NCT03309358"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0096|cit96","unstructured":"Antibiotic treatment of staphylococcus aureus in stable people with CF clinicaltrials.gov\/show\/NCT04553419"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0022-3476(82)80726-9","article-title":"Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin","volume":"101","author":"Nolan","year":"1982","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2006.01.003","article-title":"Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate","volume":"5","author":"Pai","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"8","key":"10.1002\/14651858.CD009650.pub5-BIB0099|cit99","first-page":"25","article-title":"Evaluation of tolerance and efficacy of pefloxacin in the treatment and prevention of severe infections in children with mucoviscidosis and aplastic anemia","volume":"45","author":"Postnikov","year":"2000","journal-title":"Antibiotiki i Khimioterapiia"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0100|cit100","unstructured":"Postnikov SS Semykin SJ Najimov VP Safety of fluoroquinolones in children 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P213"},{"issue":"10","key":"10.1002\/14651858.CD009650.pub5-BIB0101|cit101","first-page":"11","article-title":"Comparative yearly growth rate of children with mucoviscidosis treated and not treated with ciprofloxacin: clinicomorphological comparisons","volume":"46","author":"Postnikov","year":"2001","journal-title":"Antibiotiki I Khimioterapiia"},{"issue":"6","key":"10.1002\/14651858.CD009650.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2710.2000.00319.x","article-title":"Pharmaceutical intervention in the care of cystic fibrosis patients","volume":"25","author":"Ramstrom","year":"2000","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2125.1993.tb00380.x","article-title":"An in vivo assessment of the tobramycin\/ticarcillin interaction in cystic fibrosis patients","volume":"36","author":"Roberts","year":"1993","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009650.pub5-BIB0104|cit104","first-page":"152","article-title":"Measurement of serum tobramycin in the presence of ticarcillin or piperacillin","volume":"22","author":"Roberts","year":"1992","journal-title":"Australian Journal of Hospital Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0105|cit105","first-page":"79","article-title":"The use of ofloxacin in cystic fibrosis patients","volume":"44","author":"Romano","year":"1992","journal-title":"Minerva Pediatrica"},{"issue":"1-3","key":"10.1002\/14651858.CD009650.pub5-BIB0106|cit106","first-page":"181","article-title":"Role of home therapy with ofloxacin in patients with cystic fibrosis (CF)","volume":"38","author":"Romano","year":"1991","journal-title":"Giornale Italiano de Chemioterapia"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0107|cit107","first-page":"327","article-title":"Does tobramycin accumulate in respiratory secretions with repeated aerosol administration: a pilot study","volume":"41 Suppl 29","author":"Rosenfeld","year":"2006","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009650.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/00365549209052615","article-title":"A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis","volume":"24","author":"Salh","year":"1992","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD009650.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcf.2003.12.010","article-title":"Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid","volume":"3","author":"Serisier","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0022-3476(81)80282-X","article-title":"Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis","volume":"99","author":"Shapera","year":"1981","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD009650.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4187\/respcare.04038","article-title":"Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection","volume":"61","author":"Sharma","year":"2016","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0112|cit112","first-page":"335","article-title":"A clinically-embedded trial to evaluate the efficacy of interventions for pre-pseudomonal pathogens","volume":"48 Suppl 36","author":"Singh","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009650.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02113587","article-title":"Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis","volume":"25","author":"Smith","year":"1997","journal-title":"Infection"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ppul.10231","article-title":"Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol","volume":"36","author":"Sol\u00eds","year":"2003","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0115|cit115","first-page":"189","article-title":"Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis","volume":"82 Suppl 4A","author":"Shalit","year":"1987","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0116|cit116","first-page":"142","article-title":"Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis","volume":"82 Suppl 4A","author":"Stutman","year":"1987","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009650.pub5-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"pii: 00064","DOI":"10.1183\/23120541.00064-2015","article-title":"MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis","volume":"2","author":"Valli\u00e8res","year":"2016","journal-title":"ERJ Open Research"},{"issue":"6","key":"10.1002\/14651858.CD009650.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jcf.2013.04.009","article-title":"Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of 11 patients","volume":"12","author":"Vanderhelst","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0119|cit119","first-page":"359","article-title":"Pulmonary exacerbations and changes in lung function in CF adults with P aeruginosa treated with inhaled levofloxacin (Quinsair\u00ae) or tobramycin","volume":"51 Suppl 45","author":"Fischer","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1569-1993(16)30278-8","article-title":"History of pulmonary exacerbations (pex) AS a predictor of response to nebulized levofloxacin compared with nebulized tobramycin","volume":"2015 Suppl 1","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0122|cit122","unstructured":"Trial of aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients clinicaltrials.gov\/ct2\/show\/NCT01270347"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0123|cit123","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Van Devanter","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0124|cit124","unstructured":"Vitti TG Berg TJ Pagtakhan RD The effect of pancreatic enzyme supplement on the intestinal absorption of ampicillin and cloxacillin in children with cystic fibrosis 16th Cystic Fibrosis Club Abstracts 1975 56"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0163-4453(03)00135-X","article-title":"A randomized trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases","volume":"48","author":"Wolter","year":"2004","journal-title":"Journal of Infection"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/thx.51.4.369","article-title":"Minimisation of aminoglycoside toxicity in patients with cystic fibrosis","volume":"51","author":"Wood","year":"1996","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0127|cit127","unstructured":"Centers for Disease Control and Prevention Methicillin-resistant Staphylococcus aureus (MRSA) www.cdc.gov\/mrsa\/healthcare\/index.html"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0128|cit128","unstructured":"Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry annual data report 2020 www.cff.org\/medical-professionals\/patient-registry"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0129|cit129","unstructured":"Methicillin-resistant Staphylococcus aureus (MRSA) A Report of the UK Cystic Fibrosis Trust Infection Control Working Group 2008"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0130|cit130","unstructured":"UK CF Registry Annual Data Report 2009; March 2011 www.cysticfibrosis.org.uk\/registryreports"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0131|cit131","unstructured":"UK Cystic Fibrosis Registry 2020 Annual Data Report www.cysticfibrosis.org.uk\/sites\/default\/files\/2022-02\/2020%20Annual%20data%20report%20-%20Version%202.pdf"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0132|cit132","unstructured":"What is cystic fibrosis? www.cysticfibrosis.org.uk\/what-is-cystic-fibrosis"},{"issue":"9","key":"10.1002\/14651858.CD009650.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro2200","article-title":"Waves of resistance: Staphylococcus aureus in the antibiotic era","volume":"7","author":"Chambers","year":"2009","journal-title":"Nature Reviews Microbiology"},{"issue":"8","key":"10.1002\/14651858.CD009650.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent Methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"23","key":"10.1002\/14651858.CD009650.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0136|cit136","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022) Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD009650.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jcf.2009.11.009","article-title":"Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres","volume":"9","author":"Doe","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0138|cit138","unstructured":"European Centre for Disease Prevention and Control Surveillance Atlas of Infectious Diseases ecdc.europa.eu\/en\/healthtopics\/antimicrobial-resistance-and-consumption\/antimicrobial_resistance\/database\/Pages\/map_reports.aspx"},{"issue":"6","key":"10.1002\/14651858.CD009650.pub5-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1378\/chest.06-2756","article-title":"Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis","volume":"131","author":"Elizur","year":"2007","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD009650.pub5-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009650.pub5-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thorax.55.11.946","article-title":"Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis","volume":"55","author":"Gee","year":"2000","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0142|cit142","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0143|cit143","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD009650.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jama.2010.1115","article-title":"Health care-associated invasive MRSA infections, 2005-2008","volume":"304","author":"Kallen","year":"2010","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0924-8579(09)70551-5","article-title":"MRSA burden and interventions","volume":"34 Suppl 3","author":"Liebowitz","year":"2009","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003340","article-title":"Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization","author":"Loeb","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1099-0496(199910)28:4<231::AID-PPUL1>3.0.CO;2-2","article-title":"Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the US and Canada","volume":"28","author":"Morgan","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD009650.pub5-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcf.2011.02.004","article-title":"Treatment intensity and characteristics of MRSA infection in CF","volume":"10","author":"Muhlebach","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/jac\/dkp260","article-title":"Voluntary and mandatory surveillance for methicillin-resistant Stapylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) bacteraemia in England","volume":"64 Suppl 1","author":"Pearson","year":"2009","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD009650.pub5-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD009650.pub5-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ppul.20604","article-title":"Presence of methicillin-resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function","volume":"42","author":"Ren","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD009650.pub5-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ppul.20914","article-title":"The impact of incident methicillin-resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis","volume":"43","author":"Sawicki","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0153|cit153","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD009650.pub5-BIB0154|cit154","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001912.pub4","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","author":"Smyth","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009650.pub5-BIB0155|cit155","doi-asserted-by":"crossref","unstructured":"Vanderhelst E De Meirleir L Verbanck S Pierard D Vincken W Malfroot A Prevalence and impact on FEV 1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients Journal of Cystic Fibrosis 2012 11 1 2 7","DOI":"10.1016\/j.jcf.2011.08.006"},{"issue":"2","key":"10.1002\/14651858.CD009650.pub5-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009650.pub2","article-title":"Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","author":"Lo","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009650.pub5-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009650.pub3","article-title":"Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","author":"Lo","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009650.pub5-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD123456","article-title":"Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","author":"Lo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd009650.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T12:17:43Z","timestamp":1723465063000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009650.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009650.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]}}}